NeuroSense presents PrimeC clinical and biomarker findings at NEALS annual meeting
NRSN•NeuroSense Therapeutics will present clinical and biomarker findings from its PARADIGM Phase 2b program on Oct. 30, 2026, at the NEALS Consortium annual meeting in Clearwater, Florida.
1. Presentation details
NeuroSense Therapeutics is scheduled to present at 11:25 a.m. Eastern Time. The findings are shaping PARAGON, the planned Phase 3 study of PrimeC in ALS.
